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Abstract
Introduction: Testing for recent HIV infection can distinguish recently acquired infection from long-standing
infections. Given current interest in the implementation of recent infection testing algorithms (RITA), we report our
experiences in implementing a RITA in three pilot studies and highlight important issues to consider when
conducting recency testing in routine settings.
Methods: We applied a RITA, incorporating a limited antigen (LAg) avidity assay, in different routine HIV service-
delivery settings in 2018: antenatal care clinics in Siaya County, Kenya, HIV testing and counselling facilities in
Nairobi, Kenya, and female sex workers clinics in Zimbabwe. Discussions were conducted with study coordinators,
laboratory leads, and facility-based stakeholders to evaluate experiences and lessons learned in relation to
implementing recency testing.
Results: In Siaya County 10/426 (2.3%) of women testing HIV positive were classified as recent, compared to 46/530
(8.7%) of women and men in Nairobi and 33/313 (10.5%) of female sex workers in Zimbabwe. Across the study
setting, we observed differences in acceptance, transport and storage of dried blood spot (DBS) or venous blood
samples. For example, the acceptance rate when testing venous blood was 11% lower than when using DBS.
Integrating our study into existing services ensured a quick start of the study and kept the amount of additional
resources required low. From a laboratory perspective, the LAg avidity assay was initially difficult to operationalise,
but developing a network of laboratories and experts to work together helped to improve this. A challenge that
was not overcome was the returning of RITA test results to clients. This was due to delays in laboratory testing, the
need for multiple test results to satisfy the RITA, difficulties in aligning clinic visits, and participants opting not to
return for test results.
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Conclusion: We completed three pilot studies using HIV recency testing based on a RITA in Kenya and Zimbabwe.
The main lessons we learned were related to sample collection and handling, LAg avidity assay performance,
integration into existing services and returning of test results to participants. Our real-world experience could
provide helpful guidance to people currently working on the implementation of HIV recency testing in sub-Saharan
Africa.
Keywords: HIV, Recency testing, RITA, Zimbabwe, Kenya, Implementation
Introduction
To identify populations and areas where HIV transmis-
sion is occurring, it is helpful to distinguish among
newly diagnosed persons those who have acquired infec-
tion recently from those with a longer-standing infec-
tion. Several HIV recency tests have been developed to
make such a distinction, including the HIV limiting anti-
gen (LAg) avidity assay [1, 2]. Using LAg avidity assay
test results alone (i.e. in the absence of viral load and
antiretroviral therapy (ART) testing) to determine re-
cency status is associated with an unacceptably high pro-
portion false recent results (also known as false recency
rate), which can lead to overestimation of HIV incidence
without appropriate adjustment [3]. Recent infection
testing algorithms (RITA) combine multiple test results
to improve the classification of recent infections and de-
crease the proportion false recent. Since 2015, the
United Nations Joint Programme on HIV/AIDS
(UNAIDS) and the World Health Organization (WHO)
have recommended the inclusion of viral load testing in
RITAs to estimate incidence [4]. A study conducted in
Kenya and South Africa showed that inclusion of ART
exposure status in the RITA may further improve inci-
dence estimates [5]. While these additional steps im-
prove the accuracy of incidence estimates, they also
make implementation of the RITA more challenging.
RITAs have been used in several settings, for example
in trials [6], routine surveillance [7, 8] and in population
surveys in sub-Saharan Africa [9–12]. In 2019, the U.S.
President’s Emergency Plan for AIDS Relief (PEPFAR)
called for recency testing to be implemented among all
newly diagnosed individuals across all sites in supported
countries that had achieved certain basic progress goals
[13]. In some countries, recency test results are returned
to participants, based on either the LAg avidity assay or
the full RITA [14]. Previous studies have outlined some
of the issues that need to be considered when conduct-
ing recency testing and when interpreting test results.
These issues include differences in recency classification
by sample type [15], the effect of storage temperature on
dried blood spot (DBS) samples [16], and the need to in-
clude multiple tests in a RITA [3]. However, to the best
of our knowledge, there are no published studies about
real-word experiences in implementing recency testing
in routine service-delivery settings.
We conducted three independent, but linked, pilots of
HIV recency testing in a variety of routine service-
provision contexts in Kenya and Zimbabwe in 2018. The
three study settings were antenatal clinics providing pre-
vention of mother-to-child HIV transmission services in
Siaya County, Kenya, in HIV testing and counselling
clinics in Nairobi, Kenya, and in a national programme
for female sex workers in Zimbabwe. Here, we discuss
our experiences with the implementation of a RITA and
share lessons learned to inform other initiatives aiming




The three pilot studies were conducted in different rou-
tine service-provision settings (Table 1). In Siaya County,
Kenya we tested pregnant women aged 13 years or older
who tested HIV positive at their antenatal care visit at
one of 14 antenatal care facilities in Gem subcounty. To
determine HIV recency status, the Maxim HIV-1 LAg-
Avidity enzyme-linked immunoassay (EIA) for venous
blood was used. Recency test results were not returned
to the participants. This pilot was conducted in collabor-
ation with the Kenya Medical Research Institute (KEMR
I), and participants were linked to the KEMRI/Centers
for Disease Control and Prevention (CDC) Siaya Health
and Demographic Surveillance Site (Siaya HDSS).
In Nairobi, Kenya, we tested clients who tested HIV
positive at any of 14 Eastern Deanery AIDS Relief
Programme (EDARP) HIV testing and counselling facil-
ities. EDARP has been providing community-based HIV
and tuberculosis prevention, testing, treatment and care
services in eastern Nairobi for the past 24 years [18].
Testing was done using Maxim HIV-1 LAg-Avidity EIA
assay on dried blood spots (DBS). Results were returned
to the client at their next clinic visit. Detailed methods
and results from this pilot have been described else-
where [19].
In Zimbabwe, our study focused on female sex
workers testing HIV positive at any of six static sites of
the Sisters with a Voice programme. Both venous blood
samples and capillary DBS samples were taken. When a
woman preferred not to give a venous blood sample,
only a DBS was taken. HIV recency status was
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determined using Maxim HIV-1 LAg-Avidity EIA assays
for venous blood as well as for DBS as both samples
were taken. We compared acceptance rates between
DBS and venous blood using McNemar’s test. Results of
venous blood tests were to be made available at Sisters
clinics within 2 weeks for timely return to participants.
This pilot was conducted in collaboration with the
Centre for Sexual Health and HIV/AIDS Research
(CeSHHAR). CeSHHAR, on behalf of the Zimbabwean
National AIDS Council and Ministry of Health and
Child Care, runs the national Sisters with a Voice
programme for female sex workers, providing a range of
HIV-related services [20]. The three studies were linked
through shared protocol design, and through joint co-
ordination via a cross-pilot working group. The working
group held bi-weekly conference calls which provided a
platform for shared learnings and raising and responding
to questions and issues as they arose.
Recent infection testing algorithm
Figure 1 presents the RITA we integrated into routine
service. All individuals who were tested HIV positive
were assessed for eligibility. In Nairobi and Zimbabwe,
we did not recruit individuals for assessment of recent
infection if they self-reported a prior positive HIV anti-
body test (in Zimbabwe this had to be > 1 year ago) or if
they reported taking ART. We classified these individ-
uals as having a non-recent infection. We conducted
LAg avidity testing on the remaining participants and
classified samples with a normalized optical density
(ODn) > 1.5 as long-standing infections. For samples
with an ODn ≤1.5, we conducted viral load testing and
classified those with a viral load < 1000 as long-standing
infections and those with a viral load ≥ 1000 copies/mL
as potentially positive for recent infection. We further
characterised potentially positive samples by ART status
determined by testing for the presence of ART
Table 1 Three pilots of HIV recent infection testing in routine service settings (adapted from [17]
Siaya County, Kenya Nairobi, Kenya Sisters with a Voice, Zimbabwe
Study population Study population Study population
Pregnant women seeking antenatal care in 14
medical facilities
Clients attending any of the 14 EDARP HTC
facilities
FSW attending one of six static facilities of
the Sisters with a Voice Programme
Collaborative partner Collaborative partner Collaborative partner
Kenya Medical Research Institute (KEMRI) and the
KEMRI/CDC Siaya HDSS
Eastern Deanery AIDS Relief Programme (EDARP) Centre for Sexual Health and HIV AIDS
Research Zimbabwe (CeSHHAR-Zimbabwe)
Study period Study period Study period
February – November 2018 March – November 2018 June – November 2018
Assay Assay Assay
Maxim HIV-1 LAg-Avidity EIA venous blood Maxim HIV-1 LAg-Avidity EIA DBS Maxim HIV-1 LAg-Avidity EIA venous blood
& Maxim HIV-1 LAg-Avidity EIA DBS
Inclusion criteria Inclusion criteria Inclusion criteria
• Women aged 13 or older seeking antenatal care
in one of the included medical facilities in Siaya
County
• Willing and able to provide informed consent
• Received an HIV-antibody positive test result
• Aged 18 or older
• Unknown HIV status prior to visit
• Attending an EDARP HTC facility
• Willing and able to provide informed consent
• Received an HIV-antibody positive test result, or
presumptive positive
• FSW aged 18 or older
• Willing and able to provide informed
consent
• Received an HIV-antibody positive test
result
Exclusion criteria Exclusion criteria
• Indeterminate HIV result
• Not willing to enrol on follow-up at facility
• Taking pre-exposure prophylaxis
• Indeterminate HIV result
• Prior history of testing HIV-positive (> 1
year ago)
• On ART
Specimen collection and testing Specimen collection and testing Specimen collection and testing
• Facility nurse or laboratory phlebotomist drew a
maximum of 10 ml of venous blood
• Samples packed and transferred to KEMRI-Centre
for Global Health Research HIV Research Labora-
tory in Kisumu on a daily basis where they were
processed and stored for testing
Study nurse drew 6mL of venous blood collected
in an ethylenediaminetetraacetic (EDTA) tube and
a pipette was used to dispense venous blood on
two Whatman™ 903 Snap-Apart Cards with 5 dried
blood spots (DBS) of 70 μL each, for a total of 10
filled spots per participant
• Study or clinic nurse drew venous blood
collected in an ethylenediaminetetraacetic
(EDTA) tube.
• DBS samples were collected from
fingerprick on one Whatman™ 903 Snap-
Apart Cards with 5 dried blood spots (DBS)
of 70 μL.
• Both samples were packed and transferred
to laboratory in Harare within 36 h and
stored at -20C or below prior to testing
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metabolites (Nairobi), checking the clinic record (Siaya
County), or self-report (Zimbabwe) and classified sam-
ples from people on ART as long-standing infections
and those from people not on ART as positive for recent
infection.
LAg avidity assay
Recency assays are available for venous blood and DBS
samples [21–24]. Sample collection via DBS is regarded
as a simpler and more efficient method than venous
blood sampling, because blood drops are easier to collect
and DBS cards can be transported and stored dry at
room temperature. Venous blood results are seen as
more reliable (as they are less sensitive to haematocrit
levels than DBS) but require venepuncture, processing
to separate plasma and serum from whole blood, and
maintenance of a cold chain during transportation and
storage.
Both assay types were used in this study (Table 1).
The Maxim HIV-1 LAg-Avidity EIA (Maxim Biomedical,
Inc., Rockville, Maryland, USA) assays were performed
according to the manufacturer’s instructions for use
[25]. Wells of a microtiter plate were coated with a lim-
ited amount of multi-subtype recombinant HIV-1 anti-
gen to which antibodies bind. Specimens were diluted
and incubated for 60 min before a disassociation buffer
was added for 15 min to remove weakly-bound
antibodies. A goat anti-human, horseradish peroxidase
(HRP)-conjugated IgG was then added, which bound to
any remaining antibodies. A colour, proportionate to the
amount of HRP, was generated by adding a tetramethyl-
benzidine substrate. Optical densities were measured for
each sample and normalised by use of a calibrator speci-
men. The median was calculated from triplicate testing
of the calibrator on each plate. The normalized optical
density (ODn) was calculated by dividing the OD for
each specimen by the median calibrator OD. Specimens
with an ODn value ≤2.0 were retested in triplicate from
a fresh dilution, as required by the testing procedures.
For these specimens the final ODn value was the median
value of the triplicate test results. Anti-HIV serology was
performed on specimens showing ODn value < 0.4 to
confirm HIV antibody positivity.
Viral load and ART metabolite testing
Viral load was measured using the laboratory-based Ab-
bott m2000 RealTime system (Abbott Laboratories, Ab-
bott Park, Illinois, USA), Roche Cobas AmpliPrep/Cobas
Taqman (Roche Diagnostics International AG, Basel,
Switzerland), or similar automated platforms, according
to manufacturers’ instructions.
As including information on exposure to ART could
improve RITA performance through lowering false-
recent misclassification, Nairobi study plasma samples
Fig. 1 Recency testing algorithm (RITA) as applied in the three pilots (adapted from [17]
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assessed as potentially recent positive were tested for the
presence of antiretroviral metabolites at the Division of
Clinical Pharmacology at the University of Cape Town.
Antiretroviral metabolites, including lopinavir, ritonavir,
nevirapine, efavirenz, indinavir, saquinavir, zidovudine,
lamivudine, and stavudine, were quantified by a robust
simultaneous liquid chromatography/tandem mass spec-
trometry method [26].
Evaluation
To monitor the laboratory outputs and ensure testing
practices were of good quality, a LAg avidity assay expert
(Dr Gary Murphy, expert consultant) reviewed the out-
puts for a random sample of the plates. This included
evaluating the control samples against the permitted cri-
teria, the reproducibility of results, the comparison of
initial versus confirmatory results, and the correct enter-
ing of results. One of the authors (MdW) met with the
study coordinators of the Zimbabwe and Nairobi pilot
and observed study enrolment in a clinic as well as the
laboratory procedures in Zimbabwe. Towards the end of
the study, informal one-to-one discussions were con-
ducted with study coordinators, laboratory leads, and
facility-based stakeholders to construct an image of peo-
ple’s experiences with the different aspects of the pro-
ject. Discussion topics included experiences with
communication, field work, laboratory work, and coord-
ination, as well as recommendations and lessons learned.
Together, this provided a picture of how the study was
conducted in actuality and how it could be improved in
the future. A more detailed description of this study has
been provided elsewhere [17].
Results
Table 2 provides a summary of study recruitment,
test results, and return of these results. Across 34
pilot sites, in total 1269 people testing HIV positive
completed the RITA, of whom 89 (7.0%) were classi-
fied as positive for recent infection. A detailed de-
scription of the test results (quantitative focus) have
been presented elsewhere [17].
Sample types and transportation
Clear differences were observed in the collection of ven-
ous blood and DBS. In our pilot study in Zimbabwe,
where both sample types were collected from partici-
pants, acceptance rates for recency testing were lower
when venous blood collection was required for a sample
(n = 313, 61%) compared to a finger prick for a DBS
sample (n = 367, 72%) (p < 0.001). After sample collec-
tion, venous blood samples needed to be rapidly trans-
ported to the laboratory so that they could be
centrifuged and stored in a freezer below -20 °C to avoid
haemolysis. This proved to be challenging given recruit-
ment sites were often hours from the laboratory and re-
quired careful planning. The venous blood and DBS
samples were collected and transported at the same
time.
In Siaya county, sites were often in rural locations, and
venous blood samples were transported by motorcycle
in a cooler box in a backpack to avoid damage caused by
uneven roads. Transport was daily, as samples had to get
to the laboratory within 5 h of collection, and took 1 to
2 h. Measures to reduce transportation time, such as
having drivers stationed at a central location and avail-
able to all sites, were shown to work as none of the col-
lected samples were rejected by the laboratory for poor
quality.
In Nairobi, where sites were closer in proximity, a
driver collected samples from all sites for delivery to the
laboratory in the morning. If any additional samples
were taken later during the day, a courier picked them
up from the facilities.
Table 2 Recruitment, test results, and return of test results by pilot study
Siaya County Nairobi Zimbabwea
Participating sites 14 14 6
Eligible for HIV test 2365 50,561 4349
Tested HIV positiveb 445 628 510
Completed RITA 426 530 313
Recent infection positive prior to ART verification 11 (2.6%) 48 (9.1%) 33 (10.5%)
Number of recent infections after ART verificationc 10 (2.3%) 46 (8.7%) 33 (10.5%)
Completed RITA results returned to client NA
Recent infection 29 (60.4%) 9 (27.3%)
Long-standing infection 373 (77.1%) 24 (8.6%)
NA not applicable
aResults from venous blood tests
bIncludes people testing HIV positive for the first time in Nairobi and Zimbabwe
cART status was externally verified in Siaya County and Nairobi but not Zimbabwe
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Laboratory performance
We trained staff to perform the LAg avidity assays cor-
rectly. Despite this training, and despite most laboratory
staff being familiar with similar assays, laboratory staff in
all three settings stated that performing the LAg avidity
assay correctly was difficult and required a lot of preci-
sion. In one of the pilot studies, we repeatedly encoun-
tered invalid results from the LAg avidity assay and had
to temporarily pause recruitment during month four of
the study. To keep delays to a minimum, we transferred
testing to a back-up laboratory during the temporary
pause. By comparing operational procedures between
the original and back-up laboratories, we were able to
identify causes for the failed runs. The main reason for
invalid results was found to be incorrect calibration and
maintenance of the microplate washer. The washer was
replaced as a result of this investigation and testing
could be resumed. We learned that ensuring that these
items of equipment are available, well maintained, prop-
erly calibrated and used correctly are critical steps before
testing starts.
In recognition that a number of challenges across the
pilots were arising in relation to collecting, testing, and
returning samples, we introduced a regular call that
brought together the three in-country pilot teams, as
well as the study team based in London. Prior to this, we
were running the pilots as linked but independent stud-
ies. The laboratory technicians appreciated having such
a network of expertise as they were able to discuss the
problems they encountered, share advice, and gain
support.
Another lesson we identified retrospectively was the
potential utility of participating in an external quality as-
surance scheme. A scheme for the performance of
Maxim and Sedia LAg assays is run by Duke University’s
External Quality Assurance Program Oversight Labora-
tory (EQAPOL) [27]. This scheme distributes specimens
of known reactivity to participants who then return the
results of their testing to EQAPOL. These results are
analysed to determine agreement with the expected re-
sults thereby helping identify whether laboratories are
performing tests correctly. Signing up to this early on in
our study might have prevented the recruitment pause.
In Table 3, we summarise issues that can occur when
performing recency testing in laboratories. We present a
combination of challenges we encountered in this study
and challenges encountered by our team’s LAg avidity
assay expert in similar studies.
Organisation of fieldwork
Recency testing is increasingly implemented as part of
existing programmes and/or services [13]. As described
in the methods, we integrated recency testing into ante-
natal care services, a general HIV testing service, and a
sex workers programme. Embedding recency testing in
existing structures made it possible to get the study
started quickly and also helped to calculate the expected
sample size given that the number of clients visiting the
programme was known from previous experience. In the
Nairobi and Zimbabwe pilots, observed recruitment was
similar to expected (as calculated in our original proto-
cols based on programme activity) recruitment (600 ex-
pected and 628 recruited in Nairobi; 600 expected and
510 recruited in Zimbabwe). In Siaya County, recruit-
ment was lower than anticipated (864 expected and 445
recruited). The differences between our observed and
expected recruitment numbers reflect how the pilot
studies were reliant upon existing programme activity.
For example, in Zimbabwe, a delay in funding for
programme activities resulted in our study commencing
later than expected.
Embedding our pilots within established programmes
also required, at times, client flows to be adapted and
additional staff to be accommodated. The study required
the inclusion of additional questions to the routine client
question list. The inclusion of recency testing-related
questions in some settings lengthened the routine con-
sulting period and may have resulted in increased hesita-
tion by clients to participate in the study. To overcome
potential client concerns, staff were trained to help
people find their way around the facility and to answer
questions as they arose. Additional study requirements
in some settings resulted in an extra data clerk having to
be accommodated, which in turn resulted in having to
adapt clinic-space organisation. The impact of new tests
and personnel on clinic organisation can negatively im-
pact client flow [28].
Study recruitment was observed to vary across facil-
ities and time. In Siaya County, routine checks were
conducted to see whether we were reaching everybody
attending the facilities. This was done by comparing the
number of participants enrolled in the study to the num-
ber of participants recorded in the antenatal care regis-
ter. If a potential participant were missed, she was
reached during the subsequent visit. In Nairobi, re-
minders for recruitment were implemented into the
electronic medical records system to ensure nobody was
missed. In hindsight, it would have been useful to have
trained study staff to conduct real-time data monitoring
to pick up on variations in recruitment and data entry
errors quickly. By doing this, low recruitment or accept-
ance rates could be identified earlier on, and resolved.
Return of test results
The timely return of test results to facilities and clients
proved to be particularly challenging. We had planned
in Nairobi and Zimbabwe to schedule the return of the
recency test result to clients during their next clinic
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Table 3 Potential issues when implementing a RITA, with recommendations and additional considerations
Issue Recommendation Additional considerations
Recency
assay
Assay availability may be limited Discuss with assay manufacturer well in
advance of launch of study the number of
assays required.
This will require an understanding of the
population to be studied and the anticipated
confirmation rate.
Assay kit may not be able to be
imported into country
Ensure import permits are in place at an early
stage.
Delays to imports may affect performance of
assay if it is not stored in appropriate
condition when awaiting customs clearance.
Assay transport within country Ensure cold chain is maintained for the assay
when it is transported to local labs.
Minimising number of laboratories
performing the assay may make this easier.
Sample
types
Specimen transport within country Specimens should be transported under cold
chain. Serum/plasma specimens for LAg
testing should be separated locally before
transport. DBS specimens should ensure that
the specimen is fully dried before transport
and maintained with a desiccant.
Depending upon other tests required,
different specimens may need to be
transported under different conditions.
Training and
performance
Before testing is undertaken staff
should be trained in the performance
of the assay
Although a standard EIA this assay has
multiple pass/fail criteria and troubleshooting
errors can be complex. All users should
receive training from an experienced user
before undertaking ‘real-world’ testing. CDC
offer training panels to help users achieve
competency in the assay and help should be
sought from CDC.
This training will not only help support the
testing procedure but also the analysis tools
of the associated software.
Individuals should be monitored regularly to
confirm compliance with the testing protocol.
Testing laboratories must ensure that
Standard operating procedures are in place
for the assay detailing all steps and
conditions undertaken in their lab to allow
troubleshooting of issues and enhance data
analysis.
Assay only requires relatively basic
laboratory equipment however it is
very sensitive to issues such as
inadequate washing.
Ensure all required equipment is available and
is fully serviced, maintained and calibrated.
Equipment to be used should be itemised
before testing begins and reviewed by an
experienced individual to ensure it is suitable
for use.
Service contracts may not be in place for
some pieces of equipment so monitoring the
performance of equipment is critical to
ensure it is performing as expected. When
considering equipment even ‘common’ items
such as pipettes should be serviced and
calibrated before use.
Additional items such as bloodletting
equipment and Dried Blood spot
cards are required
These are often outside of the control of the
laboratory, but it should be ensured that the
equipment used is of the right type, within
expiry date and stored appropriately.
Details of all ancillary equipment should be
recorded and available for inspection.
Reagents should be stored as per
assays instructions for use (IFU).
Reagents are stored at a variety of
temperatures and these must be adhered to.
Temperature monitoring should be in place
for all freezers and refrigerators.
Ensure that supplies such as water are
appropriate for use following assay’s ‘IFU’.
In use reagents Wash reagents must be made as per the
assays ‘IFU’. Unless the whole kit is being
used at one time then unused reagents must
be returned to appropriate storage conditions
as soon as possible.
Testing must be performed in
accordance with the assays
‘instruction for use’
LAg assay is a generic term and at least two
manufacturers supply a version of the assay. It
is critical that the correct method is used for
each assay.
As well as two manufacturers there are
different versions of the kit dependent on
sample type being used plasma/serum or




Temperature control LAg assays are very prescriptive on incubation
times and temperatures. Assays should be
performed using incubators with precise and
recorded temperatures rather than incubated
in the open lab regardless of the current
temperature of the lab.
Regular monitoring of equipment
temperatures should be recorded and
incubators confirmed to have reached
temperature before starting assay.
Internal quality control Although the assays come with control
material, users should follow good laboratory
practice and include some specimens of
known reactivity in every test to ensure
reproducibility over time.
These results should be plotted and analysed
to look for any trends in performance.
Analysis of quality control data The manufacturer supplied analysis software
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Table 3 Potential issues when implementing a RITA, with recommendations and additional considerations (Continued)
Issue Recommendation Additional considerations
will provide quality control data on the assay
performance. Users should ensure that they
enter data correctly and ensure upper
reading OD of the spectrophotometer is
accurately entered. Users should review data
on their own internal quality control
independently as this is not captured
longitudinally by company software.
External Quality Assurance Each testing laboratory should partake in an
external quality assurance programme for the
assay. This will help provide confidence in the
results issued by each laboratory. The
programme for this assay is available via
EQAPOL.
Assay failures Laboratories should record and share any
failed runs with assay specialists. This will help
to identify if there is any systematic error
occurring with the assay and enhance the
ability to troubleshoot the assay.
Users should ensure that details of all
equipment used (Including pipettes etc) is
recorded and the items are identifiable by
serial number. Batch number of assay should
be recorded (this will be performed by the
company supplied software if used).
Assay linked analysis software Users should ensure they are using the
correct analysis software associated with the
assays. Each assay has different validation
criteria and use of the incorrect
manufacturer’s software may lead to errors in
assay interpretation and validation.
Users should also be aware to use the correct
software for plasma/serum specimens and for
DBS specimens as these differ.
Confirmatory testing Confirmatory testing must be performed from
a freshly diluted specimen. It must not be
performed from the dilution prepared for the
screening assay.
Reviewing confirmatory test data can help
determine how well an assay is being
performed as the replicates should be very
close. A wide range of values on the
confirmatory test may indicate poor pipetting
competency of the tester or poor reliability of
the pipettes.
Unusual results All unusual results should be investigated,
and retesting undertaken if warranted.
Unusual results may include specimens which
offer a low OD (which require retesting to
confirm the specimen contains antibodies to
HIV-1) or samples where the screening ODn is
significantly different from that of the con-
firmatory test. Investigations should be under-
taken to confirm that the correct specimen
was retested (or tested initially).
Many assays will not differentiate HIV-1 from




Confounding factors Users should be aware that a number of
factors can affect the performance of the test
and these should be considered when
analysing data. These include factors such as
anti-retroviral treatment of individuals and HIV
subtype prevalence.
Assay specific performance data Users should be very clear as to which assay
was used and the cut-offs applied to their
data as this impacts on the period in which
recent HIV infection can be inferred by the
assay. This is also important where multiple
HIV-1 clades are prevalent.
Results should not be issued without being
part of an algorithm to reduce the potential
for misclassification.
Over-interpretation of the data Users should be aware of the limitations of
the assay and not over interpret the data. For
example, a very low ODn may indicate a very
recent HIV infection or that the individual is
not HIV infected. As per the algorithm these
specimens should be submitted for HIV
diagnostic confirmatory testing.
Application of data trends should take into
account potential confounders such as
changes in the population, the application of
different HIC screening tests over time and
the use of different LAg assays in previous
surveys.
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visits. However, we found that this was not always feas-
ible, and clients often did not return for their results. In
Nairobi and Zimbabwe, respectively, 402 (76%) and 33
(11%) of results were finally returned to the client. In
Nairobi, only 7 (1.7%) of results were returned within 1
month and 266 (66.2%) of results were returned more
than 3months after recruitment of the participant. In
Zimbabwe, return time was highly variable and mostly
dependent on when women returned to the clinic.
Women frequently did not return to the clinic for results
and gave false contact details which hampered follow-
up. The late return of a test result may have a negative
impact on the value of the result to the client and their
utility in informing prevention activities such as partner
notification [19].
Delays in laboratory testing occurred due to failed
assay runs or increased waiting time for the samples
to be tested when recruitment was slow. As recency
testing kits are expensive, we aimed to minimise the
amount of reagents used. With every assay using 11
control wells, it proved efficient to run plates only
when enough samples were available to fill the plate.
During periods when recruitment was slow, this re-
sulted in delays. This not only delayed return of test
results but also meant that samples were stored for
different durations, potentially affecting results if stor-
age conditions were not optimal.
Another significant challenge to the timely return of
test results was the need for multiple assays to complete
the RITA. Viral load tests could be run in our participat-
ing laboratories, but ART metabolite testing required
samples to be sent to the University of Cape Town in
South Africa. This proved to be difficult for two reasons:
obtaining import and export permits within the study
period, and a testing backlog at the University of Cape
Town. Although we planned to conduct ART metabolite
testing across all three pilots, due to these two chal-
lenges, it ended up only being carried out for the Nairobi
pilot. Having an in-country facility that can conduct
ART metabolite testing would have helped overcome
these issues, although this might not be worth the costs
unless it were part of a holistic infrastructure develop-
ment. Apart from additional administrative and logistical
work, shipment for ART metabolite testing also required
high standards of storage. This raises the question of
what the optimal balance is between completing the full
RITA and quickly returning test results to participants.
An important consideration for a RITA result that lacks
an ART test component is the information and counsel-
ling provided upon the return of recency test result to a
client. The interpretation of a test result is complicated
regardless of the results because of the long window of
recent infection and the risk of false recent results. This
becomes even more complicated when exposure to ART
in unknown and has to be kept in mind when giving
feedback to clients.
Discussion
We conducted three pilot studies of HIV recency testing
in routine service-provision settings in Kenya and
Zimbabwe. A total of 1269 people completed the RITA
across the three studies, of whom 7% were found to have
a recent infection. The main implementation challenges
we faced related to sample collection and handling, LAg
avidity assay performance, integration into existing ser-
vices, and returning of test results to clients. In this
paper, we provide a detailed analysis of challenges re-
lated to laboratory procedures, together with recommen-
dations on how to address, and preferably avoid, these.
The choice to use DBS or venous blood samples af-
fected acceptance rates, transportation, and storage. Al-
though the acceptance rate for venous blood was lower
than for DBS in Zimbabwe, challenges relating to the
rapid transportation and storage of venous blood sam-
ples were overcome through careful planning and coord-
ination. Ensuring the correct performance of the LAg
avidity assay and obtaining high quality results were
more difficult than expected, underscoring the need for
adequate training and competency assessment of staff
members performing the assay. When problems with
equipment came to light, having a network of laborator-
ies and experts working together was useful to trouble-
shoot problems, promote collaboration and provide
back-up services. Because the pilots were integrated into
existing services, the study could start relatively quickly.
However, we also came across the downside of being
dependent on other programmes and having to adapt
routine practices. Returning RITA test results to partici-
pants in a timely manner proved to be particularly chal-
lenging due to delays in laboratory testing, the need for
multiple test results, alignment with clinic visits, and
participants not returning for test results. As late return
of test results may lessen the value of the results for cli-
ents, and for informing activities such as partner notifi-
cation, future programmes planning to return test
results should take account of these issues in their plan-
ning stage. Return of the test result had no impact on
treatment, as all participants that tested HIV positive
were initiated on an ART regimen, regardless of their re-
cency status.
Our study was one of the first to implement recency
testing in routine settings in sub-Saharan Africa. As re-
cency testing is currently being scaled up in PEPFAR-
supported countries to include all people with newly di-
agnosed HIV infection [13], our real-world experience
and lessons learned can provide helpful guidance to the
implementation of HIV recency testing.
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Conclusions
Our analysis showed that recency testing can be success-
fully implemented in routine settings. However, a num-
ber of challenges can be expected: challenges that can be
overcome through careful preparation, continuous mon-
itoring of test results to ensure high quality, good com-
munication, intensive coordination with routine service
providers, and quick turn-around of laboratory tests.
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